228. Secukinumab, A Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicentre, Double-Blind, Placebo-Controlled Study

Hasan Tahir, Philip Mease, Iain B. McInnes, Bruce Kirkham, Arthur Kavanaugh, Proton Rahman, Désirée van der Heijde, R. Landewé, Peter Nash, Luminita Pricop,

Lara D. Veeken · 2015 · 24 citations · 0 references

DOIFull text

Open access

Concepts

Abstract

Background: Secukinumab has demonstrated significant and rapid efficacy in the treatment of psoriasis in two phase 3 studies. We present the first randomized, multicentre, double-blind, placebo (PBO)-controlled phase III study to assess the efficacy and safety of secukinumab in patients (pts) with PsA (FUTURE 1; NCT01392326). Methods: 606 adults with active, moderate to severe PsA were randomized to secukinumab or PBO. Pts on secukinumab received 10 mg/kg i.v. loading dose at baseline, week 2 and week 4, then either 75 mg s.c. (10 i.v.→75 s.c.) or 150 mg s.c. (10 i.v.→150 s.c.) every 4 weeks from week 8. PBO was given on the same schedules. Patients naïve to anti-TNF therapy (∼70%) and those intolerant of or inadequate responders to anti-TNF therapy (TNF-IR; ∼30%), were stratified across groups. Statistical analyses for the primary and multiple secondary endpoints used non-responder imputation (binary variables), mixed-effects repeated measures model (continuous variables) and linear extrapolation (radiographic data), following a pre-defined hierarchical hypothesis testing strategy to adjust for multiplicity.